Post-earnings recap
Reported
Mon, May 11, 2015
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Ultragenyx Pharmaceutical is still in a development phase, which is reflected in their EPS miss. However, the stock rose by 6.7%, suggesting that investors are optimistic about the company's future prospects and ongoing projects. The lack of revenue data and guidance may have contributed to mixed reactions, but the market seems to be looking beyond short-term results.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.63 | N/A | -16.24% |
| Revenue | N/A | N/A | N/A |
Management remains focused on advancing their drug pipeline. They acknowledged the EPS miss but emphasized long-term growth potential.
Management highlighted ongoing commitment to pipeline development.
They expressed confidence in future product launches despite current EPS miss.